Patients will receive a 2-hour intravenous infusion of study drug (LY573636) once every 28 days. Radiological imaging scans will be performed before the first dose of study drug and then after every other treatment. Patients will be assessed for clinical progression at every visit and for response approximately every 56 days (every other cycle).